Meet the ExSyn team at Vitafoods Europe
May 05 – 07, 2026
Fira Barcelona Gran Via, Barcelona, Spain
Author archives: admin
Chemspec Europe – The Fine & Speciality Chemicals Exhibition
Meet the ExSyn team at Chemspec Europe
June 06 – 07, 2026
Koelnmesse, Germany
CPhI China – Asia’s largest pharma event
Meet the ExSyn team at CPhI China
June 16 – 18, 2026
Shanghai New International Expo Center
CPhI Korea – Your key to Korea’s Pharma Industry
Meet the ExSyn team at CPhI Korea
August 25 – 27, 2026
COEX, Seoul, Korea
CPhI Worldwide – A global community advancing human health
Meet the ExSyn team at CPhI Europe
October 06 – 08, 2026
Fiera Milano, Italy
CHINACOAT – A leading global coatings platform
Meet the ExSyn team at CHINACOAT
November 25 – 27, 2025
Shanghai New International Expo Centre (SNIEC)
CPhI India – Connecting the global pharma community in India
Meet the ExSyn team at CPhI India
November 23 – 25, 2026
IICC (Yashobhoomi) in Dwarka, Delhi
Hi Japan – Japan’s Largest Trade Show for Functional & Health Ingredients
Happy New Year!
As we approach the close of this year, we at ExSyn would like to extend our heartfelt gratitude for your trust, collaboration, and continued support. Your confidence in our products and services has been the driving force behind our growth and success.
In focus: Phosphatidylcholine 90% from Soya Lecithin
Phosphatidylcholine (PC) is one of the most important phospholipids derived from soya lecithin and represents a key structural component of cell membranes. Phosphatidylcholine 90% refers to a highly purified grade where the PC content is enriched to around 90% through specialized extraction and purification steps.
In focus: Indorez® Kota Resin
Indorez® Kota Resin is a modified non self-cured phenolic resin, it can increase rubber adhesion to steel, polyester, rayon, nylon, aramid and other fabric cord. It’s an adhesive agent, acts as methylene acceptor, can 100% replace resorcinol and resorcinol resins in resorcinol- formaldehyde-silica, enhance adhesion between rubber and reinforcing materials.
U.S. Food and Drug Administration (FDA) proposes to fast-track biosimilar approvals, cutting clinical trial requirements
The U.S. Food and Drug Administration (FDA) today announced significant action to make it faster and less costly to develop biosimilar medicines, which are lower-cost “generic” alternatives to biologic drugs that treat serious and chronic diseases.